Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.

Arteriosclerosis, thrombosis, and vascular biology - 1 Jul 2017

Sun Lei, Yang Xiaoxiao, Li Qi, Zeng Peng, Liu Ying, Liu Lipei, Chen Yuanli, Yu Miao, Ma Chuanrui, Li Xiaoju, Li Yan, Zhang Rongxin, Zhu Yan, Miao Qing Robert, Han Jihong, Duan Yajun

Abstract excerpt

OBJECTIVE: The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPARγ (peroxisome proliferator-activated receptor γ) or SREBP2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinases
Share to Aortic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Hypolipidemic Agents

Share to Plaque, Atherosclerotic

Share to Proprotein Convertase 9

Share to Receptors, Adiponectin

Share to Sterol Regulatory Element Binding Protein 2

Source

Identifiers

PMID: 28546220
DOI: 10.1161/ATVBAHA.117.309630

Genes

PCSK9
LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.PMID 28546220Read ↗

PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expressionSemantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

PPARs and their Effects on the Cardiovascular SystemSemantic proximity Read ↗

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read ↗

Proprotein Convertase Subtilisin/kexin Type 9 Links Inflammation to Vascular Endothelial Cell DysfunctionSemantic proximity Read ↗

PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-αSemantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.